

GENERAL ANNOUNCEMENT::NABOTA SUCCESSFULLY REGISTERED IN SINGAPORE

Issuer & Securities

Issuer/ Manager

HYPHENS PHARMA INTERNATIONAL LIMITED

Securities

HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5

Stapled Security

No

Announcement Details

Announcement Title

General Announcement

Date & Time of Broadcast

10-Feb-2023 18:21:37

Status

New

Announcement Sub Title

NABOTA SUCCESSFULLY REGISTERED IN SINGAPORE

Announcement Reference

SG230210OTHR488Z

Submitted By (Co./ Ind. Name)

Lim See Wah

Designation

Executive Chairman and CEO

Description (Please provide a detailed description of the event in the box below)

Please refer to the attached.

This announcement has been reviewed by the Company's Sponsor, SAC Capital Private Limited (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: +65 6232 3210) at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.

Attachments

[Hyphens - Nabota_100223.pdf](#)

Total size =668K MB



Hyphens Pharma International Limited
16 Tai Seng Street, Level 4, Singapore 534138
T: (65) 6338 8551 F: (65) 6338 8825, W:
www.hypensgroup.com
Co. Reg. No.: 201735688C GST Reg. No.:201735688C

Media Release

Nabota® successfully registered in Singapore

Singapore, 10 February 2023 – Hyphens Pharma International Limited (“**Hyphens Pharma**”, “**凯帆药剂国际有限公司**”, or the “**Company**”, and together with its subsidiaries, the “**Group**”), Singapore’s leading specialty pharmaceutical and consumer healthcare group, would like to announce that the botulinum toxin formulation Nabota® from Daewoong Pharmaceutical Co., Ltd. (“**Daewoong Pharmaceutical**”) has been successfully registered in Singapore on 20 January 2023.

Botulinum toxin, commonly referred to as botox, is a neuromodulator for cosmetic use, such as facial wrinkle improvement. Nabota® is a premium high-purity botulinum toxin based on Daewoong Pharmaceutical’s patented Hi-Pure™ technology that minimises impurities, and is characterised by its high safety, rapid effect, and uniform spreading power.

Nabota® is approved by the U.S. Food and Drug Administration (“**FDA**”) and the Company’s subsidiary Hyphens Pharma Pte. Ltd. will be handling the distribution and sales in Singapore.

Lim See Wah, Executive Chairman and CEO of Hyphens Pharma, said: *“We are happy to partner Daewoong Pharmaceutical to bring in Nabota®, as we see a growing demand for facial wrinkle improvement due to aging populations. With the addition of Nabota®, Hyphens Pharma continues to advance its position as ASEAN’s leading specialty pharmaceutical company.”*

End.

About Hyphens Pharma International Limited**(www.hyphensgroup.com)**

Hyphens Pharma International Limited and its subsidiaries (the "Group") is Singapore's leading specialty pharmaceutical and consumer healthcare group, leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in Singapore, Vietnam, Malaysia, Indonesia and the Philippines, and is supplemented by a marketing and distribution network covering 10 other markets – Bangladesh, Brunei, Cambodia, China, Hong Kong S.A.R., Macau S.A.R., Myanmar, Oman, South Korea and Sri Lanka.

Singapore is the Group's regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based. The Group's core business comprises the following segments: Specialty Pharma Principals, Proprietary Brands, and Medical Hypermart & Digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies and an online pharmacy for doctors to prescribe and have medications delivered to their patients' homes.

Issued on behalf of : **Hyphens Pharma International Limited**
For media enquires contact : Mr Derek Chng / Mr Gerald Woon
Email / DID / Mobile : derekchng@cogentcomms.com / (65) 6704 9285 / (65) 9638 8635
woon@cogentcomms.com / (65) 6704 9268 / (65) 9694 8364

This media release has been reviewed by the Company's sponsor, SAC Capital Private Limited (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this media release, including the correctness of any of the statements or opinions made or reports contained in this media release.

The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: (65) 6232 3210) at 1 Robinson Road, #21- 00 AIA Tower, Singapore 048542.